METHOD FOR DETERMINING THE RISK OF HEPATOCELLULAR CARCINOMA IN THE PATIENTS WITH CHRONIC HEPATITIS C Russian patent published in 2020 - IPC G01N33/574 G01N33/68 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, gastroenterology and infectious diseases, and enables determining a risk of developing hepatocellular carcinoma in the patients with chronic hepatitis C. That is ensured by using a set of laboratory values of patient's venous blood and its biological indices and calculating the risk level by the formulas: F₁=-73.1676+0.4846×A+6.5932×S+22.3483×RBCs+0.024×ALT+0.0015×AFP+0.056×OPN; F₂=-72.7678+0.2393×A+9.9954×S+24.3663×RBCs+0.0018×ALT+0.0012×AFP-0.0009×OPN; where A is patient's age, S is sex (1 is male, 2 is female), RBCs are erythrocytes (×10¹²/l), ALT is alanine aminotransferase (Un./l), AFP is alpha-fetoprotein (IU/ml), OPN is osteopontin (ng/ml). If F₁>F₂ high risk of developing hepatocellular carcinoma is detected, and if F₁<F₂, low risk of developing hepatocellular carcinoma in the patients with chronic hepatitis C is determined.

EFFECT: invention provides higher sensitivity and accuracy of determining the risk of developing hepatocellular carcinoma in the patients with chronic hepatitis C.

1 cl, 2 ex, 1 tbl